Differentiated thyroid cancer is treated by (near) total thyroidectomy followed by radioiodine
(131 I) ablation of the residual active tissue in the thyroid bed. Controversy remains …

BACKGROUND Radioiodine has been used for more than a half‐century to ablate thyroid
remnants following thyroid surgery, but a single optimal dose has not been established. We …

The aims of this study were to evaluate the efficacy of an empirically determined 'fixed'high
ablative dose of radioiodine (131 I) therapy and to determine the utility of ultrasonography …

Remnant ablation can be achieved by either administering an empiric fixed dose or using
dosimetry-guided techniques. Because of the technical and logistic difficulties, most centers …

Detection of residual tissue after thyroidectomy for papillary or follicular thyroid carcinoma
may be performed using diagnostic imaging with either 123I or 131I. The former is often …

Objective We conducted a stratified randomized equivalence/noninferiority trial from January
2001 to December 2006 to determine whether lower administered activities are as effective …

[en] This study was performed under the auspices of IAEA project (i) to evaluate the efficacy
of low (50 mCi) vs. high (100 mCi) dose I-131 for post operative remnant ablation in …

Background In the management of patients with differentiated thyroid carcinoma, direct
comparison of the presence of scintigraphic stunning after a diagnostic dose of 131 I with …

Objective To review and comment on current indica tions for radioiodine remnant ablation
(RRA) in patients with differentiated thyroid cancer. Methods The stratification of patients as …

Methods In 87 patients with thyroid carcinoma treated with 0.85-9.55 GBq (23-258 mCi) of
131I to ablate residual thyroid tissue, the cumulative absorbed dose and the initial dose rate …